UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Mechanistic Study of HCV Polymerase Inhibitors at Individual Steps of the Polymerization Reaction

Biochemistry (Easton), 2006-09, Vol.45 (38), p.11312-11323

2006

Volltextzugriff (PDF)

Ordered accumulation of mutations in HIV protease confers resistance to ritonavir

Nature medicine, 1996-07, Vol.2 (7), p.760-766

1996

Volltextzugriff (PDF)

Human Serum Attenuates the Activity of Protease Inhibitors toward Wild-Type and Mutant Human Immunodeficiency Virus

Virology (New York, N.Y.), 1998-10, Vol.250 (2), p.255-262

1998

Volltextzugriff (PDF)

In Vitro Antiviral Interaction of Lopinavir with Other Protease Inhibitors

Antimicrobial Agents and Chemotherapy, 2002-07, Vol.46 (7), p.2249-2253

2002

Volltextzugriff (PDF)

Estimation of Serum-Free 50-Percent Inhibitory Concentrations for Human Immunodeficiency Virus Protease Inhibitors Lopinavir and Ritonavir

Antimicrobial Agents and Chemotherapy, 2004-08, Vol.48 (8), p.2911-2917

2004

Volltextzugriff (PDF)

Synthesis and SAR studies of potent HIV protease inhibitors containing novel dimethylphenoxyl acetates as P 2 ligands

Bioorganic & medicinal chemistry letters, 2003-11, Vol.13 (21), p.3657-3660

2003

Volltextzugriff (PDF)

Symmetry-based inhibitors of HIV protease. Structure-activity studies of acylated 2,4-diamino-1,5-diphenyl-3-hydroxypentane and 2,5-diamino-1,6-diphenylhexane-3,4-diol

Journal of medicinal chemistry, 1993-02, Vol.36 (3), p.320-330

1993

Volltextzugriff (PDF)

ABT-378, a Highly Potent Inhibitor of the Human Immunodeficiency Virus Protease

Antimicrobial Agents and Chemotherapy, 1998-12, Vol.42 (12), p.3218-3224

1998

Volltextzugriff (PDF)

ABT-538 is a Potent Inhibitor of Human Immunodeficiency Virus Protease and has High Oral Bioavailability in Humans

Proceedings of the National Academy of Sciences - PNAS, 1995-03, Vol.92 (7), p.2484-2488

1995

Volltextzugriff (PDF)

Discovery of Ritonavir, a Potent Inhibitor of HIV Protease with High Oral Bioavailability and Clinical Efficacy

Journal of medicinal chemistry, 1998-02, Vol.41 (4), p.602-617

1998

Volltextzugriff (PDF)

Novel lopinavir analogues incorporating non-Aromatic P-1 side chains—Synthesis and structure–Activity relationships

Bioorganic & medicinal chemistry letters, 2002-11, Vol.12 (21), p.3101-3103

2002

Volltextzugriff (PDF)

Pseudo-symmetrical difluoroketones: Highly potent and specific inhibitors of HIV-1 protease

FEBS letters, 1993-08, Vol.329 (1), p.144-146

1993

Volltextzugriff (PDF)

Synthesis and antiviral activity of P1′ arylsulfonamide azacyclic urea HIV protease inhibitors

Bioorganic & medicinal chemistry letters, 2004-08, Vol.14 (15), p.4075-4078

2004

Volltextzugriff (PDF)

Novel lopinavir analogues incorporating heterocyclic replacements of six-member cyclic urea––synthesis and structure–activity relationships

Bioorganic & medicinal chemistry letters, 2004-05, Vol.14 (10), p.2643-2645

2004

Volltextzugriff (PDF)

Synthesis and SAR studies of potent HIV protease inhibitors containing novel dimethylphenoxyl acetates as P2 ligands

Bioorganic & medicinal chemistry letters, 2003-11, Vol.13 (21), p.3657-3660

2003

Volltextzugriff (PDF)

Synthesis and structure-activity relationships of a novel series of HIV-1 protease inhibitors encompassing ABT-378 (Lopinavir)

Bioorganic & medicinal chemistry letters, 2002-04, Vol.12 (8), p.1185-1187

2002

Volltextzugriff (PDF)

Corrigendum to “Synthesis and antiviral activities of the major metabolites of the HIV protease inhibitor ABT-378 (Lopinavir)”: [Bioorg. Med. Chem. Lett. 11 (2001) 1351]

Bioorganic & medicinal chemistry letters, 2004-05, Vol.14 (10), p.2695-2695

2004

Volltextzugriff (PDF)

Structure-based, C2 symmetric inhibitors of HIV protease

Journal of medicinal chemistry, 1990-10, Vol.33 (10), p.2687-2689

1990

Volltextzugriff (PDF)

Synthesis and antiviral activities of the major metabolites of the HIV protease inhibitor ABT-378 (Lopinavir)

Bioorganic & medicinal chemistry letters, 2001-06, Vol.11 (11), p.1351-1353

2001

Volltextzugriff (PDF)

Design of orally bioavailable, symmetry-based inhibitors of HIV protease

Bioorganic & medicinal chemistry, 1994-09, Vol.2 (9), p.847-858

1994

Volltextzugriff (PDF)

Evaluation of furofuran as a P2 ligand for symmetry-based HIV protease inhibitors

Bioorganic & medicinal chemistry letters, 1996-12, Vol.6 (23), p.2847-2852

1996

Volltextzugriff (PDF)

Potent piperazine hydroxyethylamine HIV protease inhibitors containing novel P 3 ligands

Bioorganic & medicinal chemistry letters, 1998-12, Vol.8 (24), p.3531-3536

1998

Volltextzugriff (PDF)

Potent piperazine hydroxyethylamine HIV protease inhibitors containing novel p3 ligands

Bioorganic & medicinal chemistry letters, 1998-12, Vol.8 (24), p.3531-3536

1998

Volltextzugriff (PDF)

Evaluation of substituted benzamides as P2 ligands for symmetry-based inhibitors of HIV protease

Bioorganic & medicinal chemistry letters, 1995-11, Vol.5 (22), p.2725-2728

1995

Volltextzugriff (PDF)

Evaluation of furofuran as a P 2 ligand for symmetry-based HIV protease inhibitors

Bioorganic & medicinal chemistry letters, 1996-12, Vol.6 (23), p.2847-2852

1996

Volltextzugriff (PDF)

1 – 25 von 34

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(30)
Mit Volltextzugriff
(33)

Publikationsform

Artikel
(34)

Sprache

Englisch
(34)
Japanisch
(8)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

Mechanistic Study of HCV Polymerase Inhibitors at Individual Steps of the Polymerization Reaction

Ordered accumulation of mutations in HIV protease confers resistance to ritonavir

Human Serum Attenuates the Activity of Protease Inhibitors toward Wild-Type and Mutant Human Immunodeficiency Virus

In Vitro Antiviral Interaction of Lopinavir with Other Protease Inhibitors

Estimation of Serum-Free 50-Percent Inhibitory Concentrations for Human Immunodeficiency Virus Protease Inhibitors Lopinavir and Ritonavir

Synthesis and SAR studies of potent HIV protease inhibitors containing novel dimethylphenoxyl acetates as P 2 ligands

Symmetry-based inhibitors of HIV protease. Structure-activity studies of acylated 2,4-diamino-1,5-diphenyl-3-hydroxypentane and 2,5-diamino-1,6-diphenylhexane-3,4-diol

ABT-378, a Highly Potent Inhibitor of the Human Immunodeficiency Virus Protease

ABT-538 is a Potent Inhibitor of Human Immunodeficiency Virus Protease and has High Oral Bioavailability in Humans

Discovery of Ritonavir, a Potent Inhibitor of HIV Protease with High Oral Bioavailability and Clinical Efficacy

Novel lopinavir analogues incorporating non-Aromatic P-1 side chains—Synthesis and structure–Activity relationships

Pseudo-symmetrical difluoroketones: Highly potent and specific inhibitors of HIV-1 protease

Synthesis and antiviral activity of P1′ arylsulfonamide azacyclic urea HIV protease inhibitors

Novel lopinavir analogues incorporating heterocyclic replacements of six-member cyclic urea––synthesis and structure–activity relationships

Synthesis and SAR studies of potent HIV protease inhibitors containing novel dimethylphenoxyl acetates as P2 ligands

Synthesis and structure-activity relationships of a novel series of HIV-1 protease inhibitors encompassing ABT-378 (Lopinavir)

Corrigendum to “Synthesis and antiviral activities of the major metabolites of the HIV protease inhibitor ABT-378 (Lopinavir)”: [Bioorg. Med. Chem. Lett. 11 (2001) 1351]

Structure-based, C2 symmetric inhibitors of HIV protease

Synthesis and antiviral activities of the major metabolites of the HIV protease inhibitor ABT-378 (Lopinavir)

Design of orally bioavailable, symmetry-based inhibitors of HIV protease

Evaluation of furofuran as a P2 ligand for symmetry-based HIV protease inhibitors

Potent piperazine hydroxyethylamine HIV protease inhibitors containing novel P 3 ligands

Potent piperazine hydroxyethylamine HIV protease inhibitors containing novel p3 ligands

Evaluation of substituted benzamides as P2 ligands for symmetry-based inhibitors of HIV protease

Evaluation of furofuran as a P 2 ligand for symmetry-based HIV protease inhibitors

Suchergebnisse filtern